We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biotech stocks combine scientific innovation with substantial R&D investment in cutting edge medicine.
Biotech sector includes companies focused on gene editing and breakthroughs in rare disease treatment.
Biotech stocks are higher risk, but with higher potential for reward for companies that succeed.
The biotech sector continues to draw intense investor interest — from innovation in gene editing and mRNA to breakthroughs in rare disease therapies. But with high risk comes high reward, and separating long-term winners from speculative bets is more important than ever.
Are Biotech Stocks a Good Investment Long-Term?
Biotech companies can deliver extraordinary upside when their clinical programs succeed — but the path is fraught. Long-term investing in biotech often hinges on believing in a company’s pipeline, cash runway and capacity to navigate regulatory hurdles. Many top biotechs have matured past early-stage risk, with commercial revenues and established R&D engines, making them more resilient in volatile markets.
Meanwhile, broader trends like aging populations, precision medicine, and platform technologies (like gene therapy and mRNA) bolster the long-term case. However, interest rate swings, clinical failures and capital burn remain real threats. For investors with sufficient time horizon and risk tolerance, biotechs offer a compelling opportunity.
Here, we analyze and rank the best biotech stocks to buy now ranked on a blend Zacks Rank signals, Style Scores and fundamentals:
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%.
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Value ScoreA
Growth ScoreA
Momentum ScoreA
VGM ScoreA
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.
Neurocrine Biosciences is a neuroscience-focused biotech advancing commercial therapies and a diversified R&D engine. INGREZZA should benefit from sizable remaining TD opportunity, expanded VMAT2 prescriber outreach and IP protection to 2038, while CRENESSITY may gain from sales-force expansion, ongoing studies in quality-of-life and long-term safety and outcomes.
Potential Risks
Risks include commercialization uncertainty for INGREZZA and CRENESSITY, product-candidate development setbacks, pricing controls, reimbursement limits, competition and generic entrants pressure.
Forecast
A Zacks Rank #2 (Buy), with Style Scores of B for Value and Momentum B, and A for Growth, points to a balanced revision profile. The growth is the clearest support, while valuation is not stretched versus many profitable biotechs. The chart shows 2025 EPS estimates recovering sharply from 2024, 2026–2027 estimates recently choppy but still high, and a series of beats that helps explain the stock’s steady rebound, despite occasional post-earnings stock swings.
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%.
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Value ScoreA
Growth ScoreA
Momentum ScoreA
VGM ScoreA
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.
GRAIL is advancing Galleri, a multi-cancer early detection blood test designed to supplement standard-of-care screening. The stock may benefit as NHS-Galleri and PATHFINDER 2 data support broader confidence in real-world use, showing stage-shift potential, substantially higher screening-detected cancers, low false positives, accurate cancer-signal origin prediction and patient-centered diagnostic pathways.
Potential Risks
Risk remains tied to clinical interpretation, regulatory and payer decisions, and adoption, since NHS-Galleri missed its combined Stage III and IV primary endpoint despite supportive secondary findings overall.
Forecast
A Zacks Rank #3 (Hold) suggests estimates are not yet moving strongly enough to confirm the rally. The B Momentum Score fits the chart’s vertical price advance, but Value F and Growth D signal limited fundamental support. The chart shows consensus lines clustered and mostly flat through 2028, recent beats, and a price that has far outrun estimates, raising volatility risk for new buyers.
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%.
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Value ScoreA
Growth ScoreA
Momentum ScoreA
VGM ScoreA
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.
CareDx operates at the intersection of molecular diagnostics, transplant monitoring and emerging specialty-oncology testing. Its pipeline could broaden growth through AlloHeme, AlloSure Liver and HistoMap Kidney, while the Naveris acquisition may add a reimbursed MRD platform for viral-mediated cancers. EMR workflow tools, evidence-generation programs and solutions-selling may strengthen adoption across specialty-provider networks and expand its portfolio TAM over the longer term.
Potential Risks
Risks include reimbursement changes, LCD impact, transaction execution, integration of Naveris, evidence-development needs, and dependence on adoption across specialty-provider settings.
Forecast
A Zacks Rank #3 with Growth A and Momentum B indicate strong forward potential, but the Value D score tempers the setup. The chart shows price stabilizing after a steep fall, 2025 estimates rising materially, and 2026–2027 estimates recently revised lower from prior peaks. Several recent beats support the turnaround case, but consensus volatility argues for patience until durability is clearer.
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%.
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Value ScoreA
Growth ScoreA
Momentum ScoreA
VGM ScoreA
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.
Veracyte is a cancer diagnostics platform company spanning thyroid, prostate, breast, bladder and MRD testing. Its growth outlook could benefit from Prosigna LDT launch, Medicare-covered TrueMRD in MIBC, Decipher adoption across prostate risk levels, Afirma share gains, expanding clinical signatures, digital pathology assets and a diagnostics platform built on broad genomic assays, clinical data and evidence generation globally over time.
Potential Risks
Risks include product launch, commercialization and reimbursement challenges, proving genomic-test utility, integration of C2i Genomics, scaling global operations, macro volatility and clinical-performance uncertainty and investor confidence over time.
Forecast
A Zacks Rank #3 keeps the signal neutral, but Growth A suggests estimates still have quality. The Value D score is the main offset, while Momentum C matches the recent pullback. The chart shows 2025–2027 consensus rising after earlier cuts, 2028 jumping higher, and multiple recent beats. Price is recovering toward prior highs, but estimate follow-through matters most.
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%.
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Value ScoreA
Growth ScoreA
Momentum ScoreA
VGM ScoreA
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.
ImmunityBio is a commercial-stage immunotherapy company developing cytokine, vaccine and cellular-therapy platforms. ANKTIVA could benefit from broader market access, NCCN recognition, J-Code reimbursement, UK, EU and Saudi approvals, plus potential expansion in papillary-only, BCG-naïve NMIBC, recombinant BCG, NSCLC checkpoint failure, lymphopenia and pancreatic cancer programs, supporting a multi-catalyst biotech growth outlook as trials and regulatory reviews further advance over time.
Potential Risks
Risks include launch execution, clinical-development uncertainty, product shortages, manufacturing disruptions, financing needs, commercialization challenges, hiring retention, collaborations and patent protection for candidates and technologies globally, commercially.
Forecast
A Zacks Rank #3 indicates estimates are balanced rather than decisively improving. Growth A and Momentum B support the upside case, but Value F reflects losses and valuation uncertainty. The chart shows a huge price spike followed by retreat, while 2025–2027 estimates are uneven and 2028 expectations sit higher. Recent mixed surprise signals fit a volatile launch-stage story, not a settled one.
The Zacks Rank is a proprietary stock-rating model that uses trends in earnings estimate revisions and earnings-per-share (EPS) surprises to classify stocks into five groups: #1 (Strong Buy), #2 (Buy), #3 (Hold), #4 (Sell) and #5 (Strong Sell). The Zacks Rank is calculated through four primary factors related to earnings estimates: analysts' consensus on earnings estimate revisions, the magnitude of revision change, the upside potential and estimate surprise (or the degree in which earnings per share deviated from the previous quarter).
Zacks builds the data from 3,000 analysts at over 150 different brokerage firms. The average yearly gain for Zacks Rank #1 (Strong Buy) stocks is +24.00% per year from January, 1988, through May 4, 2026.
Selections for Best Biotech Stocks are based on the current top ranking stocks based on Zacks Indicator Score, Style Scores and fundamentals. For this list, only companies that have average daily trading volumes of 100,000 shares or more of 135 biotech companies listed on the New York Stock Exchange or Nasdaq. All information is current as of market open, June 18, 2026.
General Biotech Investment Questions
What Are Biotech Stocks?
Biotech stocks are shares of companies that use biological systems and organisms to develop new drugs, therapies, and diagnostics. These firms invest heavily in research & development and often carry greater risk than traditional pharmaceutical companies.
Therapeutic biotechs: Develop specific drug candidates (e.g., rare disease, oncology).
Service biotechs: Provide research tools, reagents, or contract research services.
What Are the Benefits of Buying Biotech Stocks?
High upside: Successful trials or approvals can lead to big gains.
Innovative exposure: Access to cutting-edge science (e.g., gene therapy).
Diversification: Biotech can be a non-cyclical growth lever in a portfolio.
Partnering potential: Smaller biotech firms are often acquired by larger pharma.
What Are the Risks of Buying Biotech Stocks?
Clinical risk: Many drugs fail in trials
Cash burn: R&D is expensive, and many biotechs depend on funding.
Regulatory risk: FDA decisions can make or break a company.
Volatility: Stock prices swing wildly on news.
Biotech Stocks vs. Biotech ETFs
Stocks: Higher potential reward, but higher risk and volatility
ETFs: Diversified exposure, smoother ride, less binary outcomes
Which is right depends on your risk tolerance and conviction in individual companies.
Why Are Biotech Stocks So Volatile?
Clinical trial outcomes are binary (success/failure).
Regulatory approvals depend on strict criteria.
Biotechs often raise capital, diluting shareholders.
News-driven: trial results, partnership deals, or FDA news can swing sentiment.
Is It Too Late to Invest in Biotech Stocks?
Not necessarily. While some biotechs (especially large-caps) may look fully valued, many smaller, clinical-stage companies still offer asymmetric upside. Plus, emerging trends — gene editing, synthetic biology, AI-driven drug discovery — continue to open new frontiers.
Best Biotech ETFs
Not all investors want to take on the risk of single biotechs. Below are some top ETFs that offer diversified exposure:
iShares Biotechnology ETF (IBB): Focuses on large-cap biotech names, offering lower volatility compared to smaller biotechs.
SPDR S&P Biotech ETF (XBI): Equal-weighted, which means more exposure to mid- and small-cap biotech companies — higher risk, potentially higher reward.
VanEck Biotech ETF (BBH): Concentrated in major pure-play biotech names.
These ETFs help mitigate the binary risk inherent in individual biotech names by spreading exposure across many companies.
Biotech Stocks Trends and Forecast
What Biotech Stocks Could Benefit from New FDA Approvals?
Sarepta (SRPT): Pipeline in DMD and other neuromuscular disorders.
Beam (BEAM): Base-editing therapies could attract regulatory attention as clinical data matures.
Arcellx: Its CAR-T programs (e.g., anito-cel) could hit registrational milestones soon.
Which Biotech Firms Are Leading in Gene Editing or mRNA?
What Are the Most Promising Biotech Trends for 2025/2026?
Base editing and next-gen CRISPR.
Synthetic biology for therapeutics.
Precision medicine for rare diseases.
AI-driven drug discovery.
Cell and gene therapies for “undruggable” conditions.
How Does Interest Rate Policy Affect Biotech Valuations?
Higher interest rates make future cash flows less valuable, which disproportionately affects pre-commercial biotech companies. Biotechs with strong cash reserves, recurring revenues, or partnerships may weather a high-rate environment better than early-stage names.
What Startups Could Be the Next Big Biotech Breakout?
Some emerging companies to watch include those in base editing (like Beam) or synthetic biology (like Twist Bioscience). Also, small gene therapy firms that prove safety and efficacy could be acquisition targets.
How to Select Biotech Stocks
How to Evaluate a Biotech Company’s Pipeline
Examine clinical trial phases and data (Phase 1–3).
Check regulatory designations (Orphan, Fast Track, Breakthrough).
Assess manufacturing strategy (can they scale?)
Review partnerships with big pharma.
What Financial Metrics Should I Look at When Selecting Biotech Stocks?
Cash runway — Months until they need to raise capital.
Burn rate — How fast they spend R&D cash?
Debt levels — To help understand leverage risk.
Revenue sources — If any (e.g., royalties, partnerships).
Valuation multiples — P/E for commercial companies, or price-to-cash for R&D firms.
Which Biotech Companies Are Using AI for Drug Discovery?
Several biotech firms now leverage AI to speed up target identification, optimize molecules, and predict clinical success. While specific names vary, more platform-focused biotechs (especially in synthetic biology and precision medicine) are adopting AI broadly.
Advanced or Thematic Biotech Investing
Best Gene Therapy, Immunotherapy, or Synthetic Biology Stocks
Companies combining AI with biology to accelerate drug development are particularly exciting. Though many remain private, public players using AI in drug discovery or platform development may include synthetic biology firms and next-gen therapeutic companies.
Small-Cap vs. Large-Cap Biotech Investing Strategies
Small-Cap: Higher risk/reward; ideal for speculative, event-driven plays.
Large-Cap: More stability, some revenue streams, diversified pipelines.
Balanced Approach: Use ETFs for broad exposure + pick 1–2 individual names for high conviction.
How FDA Approval Cycles Impact Biotech Valuations
Each clinical milestone (Phase 2 readout, Phase 3 initiation, NDA/BLA filing) can trigger major revaluations. Investors often build models around key FDA dates, trial data, and partner commitments. Failure or delay can lead to steep losses; success can lead to multi-bagger returns.
View the Zacks #1 Rank List
Buy 
